PHARMACOECONOMICS GUIDELINES FROM APOR WILL ADDRESS DISCOUNTING, LEVELS OF EVIDENCE; EXPLICIT DISCLOSURE IS OVERARCHING PRINCIPLE OF FLEXIBLE DOCUMENT
The Association for Pharmacoeconomics & Outcomes Research is developing consensus guidelines for economic evaluation of pharmaceutical therapy that will attempt to integrate the needs of academia, industry and managed care, APOR founding member Steven Finder, MD, Department of Defense Pharmacoeconomic Center, said May 13 at the association's inaugural annual meeting in Philadelphia.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth